Among three new models for KCNMA1 channelopathy, the most severe gain-of-function variant (Kcnma1N999S/WT) displays a particular type of immobilizing paroxysmal dyskinesia observed in patients, including amphetamine responsiveness.
A disease-associated polymorphism in a related protein that regulates neurotransmitter release reveals that antiviral protein IFITM3 forms oligomers to rigidify membranes and inhibit virus fusion with cells.
